14 results about "Fixed-dose combination" patented technology

The invention relates to a pharmaceutical composition comprising a fixed dose combination of (a) Netupitant or salt or hydrate thereof, and (b) Palonosetron or salt or hydrate thereof, in a single pharmaceutical unit. The invention further relates to a method of preparing a pharmaceutical composition in the form of a tablet, the method comprising: (i) wet granulating a dry mixture comprising Netupitant or a salt or hydrate thereof, filler, a binder, a disintegrant, and optionally a surfactant and / or a lubricant, with a solution comprising Palonosetron or a salt or hydrate thereof, and optionally a surfactant and / or a binder, to produce granules, (ii) blending the granules with a lubricant, a disintegrant and a glidant, and optionally a filler, and (iii) compressing of the lubricated granules to produce a tablet. The invention further relates to the pharmaceutical composition for use in the treatment and / or prevention of nausea and / or vomiting, preferably in the treatment and / or prevention of acute or delayed nausea and vomiting associated with chemotherapy, such as highly or moderately emetogenic cancer chemotherapy, for example cisplatin cancer chemotherapy.

The present disclosure relates generally to pharmaceutical dosage forms comprising azacitidine and chidaridine.

The present disclosure provides for fixed-dose combination formulations comprising flavoxate or a pharmaceutically acceptable salt thereof and at least one β3-adrenergic receptor agonist, along with methods of making and using the same to treat symptoms associated with prostate, bladder, urinary tract, and pelvic conditions.

The present disclosure relates to compositions and methods for treating hormone receptor positive (HR+) cancer with (Z)-endoxifen and a CDK4 / 6 inhibitor, such as abemaciclib. The disclosure is based on the discovery that (Z)-endoxifen and abemaciclib have synergistic effects on reducing tumor growth and proliferation in breast cancer models. The disclosure also provides fixed dose combinations of (Z)-endoxifen and abemaciclib, which offers advantages in terms of convenience and compliance. The compositions and methods are suitable for treating subjects with hormone receptor positive (HR+) and human epidermal growth factor receptor 2 negative (HER2-) breast cancer, especially those who are contraindicated for aromatase inhibitor therapy and / or ovarian suppression therapy.

Embodiments disclosed herein are directed to fixed compositions comprising brimonidine and timolol for lowering intraocular pressure and treating glaucoma.

The present invention relates to pharmaceutical compositions comprising fixed dose combinations of a DPP-4 inhibitor drug and / or a SGLT-2 inhibitor drug, and metformin XR, processes for the preparation thereof, and their use to treat certain diseases.

The present application relates to an inhalable liquid composition suitable for nebulization comprising a fixed dose combination comprising glycopyrronium, formoterol and budesonide for treating a pulmonary disorder(s). The present application also relates to a process for preparing such a composition comprising a fixed dose combination comprising glycopyrronium, formoterol and budesonide.

A composition useful for treating immune-mediated inflammatory diseases or cancer in mammalian subjects. The composition includes a synergistic combination of a cannabis derived compound, and a medicinal mushroo

The present disclosure relates generally to pharmaceutical dosage forms comprising azacitidine and cedazuridine.

The present disclosure relates to combinations of obicetrapib and ezetimibe, or their salts, solvates or derivatives thereof. The disclosure further describes the use of ezetimibe and obicetrapib, e.g. in the form of a fixed dose combination product, for preparation of medicaments and method of treatment of subjects requiring reduction in LDL-cholesterol or those suffering from hyperlipidemia or mixed dyslipidemia.

The present invention relates to a composition comprising Mesdopetam alone or in combination with proton pump inhibitor which can be administered either separately i.e. by co-administration or in a fixed dose combination (FDC) in the treatment of gastrointestinal and related disorders. The present invention provides use of mesdopetam in the manufacture of a medicament for the treatment of gastrointestinal disorders in a subject in need thereof wherein the medicament is to be administered to the subject. The present invention also relates to a method of treating gastrointestinal diseases in a subject in need thereof comprising administering to the subject mesdopetam and pharmaceutical composition.

This invention belongs to the field of pharmaceutical technology, specifically relating to a pharmaceutical composition for the prevention and / or treatment of cancer. In particular, it relates to a pharmaceutical composition comprising a CDK4 / 6 inhibitor compound of formula (I) or a pharmaceutically acceptable salt thereof, and a second therapeutic agent or a pharmaceutically acceptable salt thereof, in a fixed ratio or fixed dose combination; the use of the above pharmaceutical composition in the preparation of a medicament for the prevention and / or treatment of cancer; and a cassette containing the pharmaceutical composition.

The disclosure provides methods for the for treatment of psychosis, such as schizophrenia, or depression (such as bipolar depression) and / or anxiety, comprising administering to a patient in need thereof, (i) a 5-HT2A or 5-HT2A / D2 receptor ligand, for example a substituted heterocycle fused gamma-carboline as described herein, in free, pharmaceutically acceptable salt or prodrug form, and (ii) a nitric oxide donor, separately (sequentially or simultaneously), or in combination (e.g., in a fixed dose combination).

The present invention relates to the combination of ibuprofen in the form of a pharmaceutically acceptable salt and tramadol or a pharmaceutically acceptable salt thereof, for use in the treatment of pain in humans, wherein the dosage of ibuprofen in the combination is between 350 mg and 450 mg and the dosage of tramadol is between 35 mg and 40 mg, expressed as an equivalent weight of tramadol hydrochloride. The combination is suitable for the treatment of moderate to severe pain, of chronic or acute origin and is particularly effective for those patients suffering from more severe pain. It also relates to a pharmaceutical composition comprising said fixed dose combination of ibuprofen and tramadol.